Valuation : Daxor Corporation

Market Cap 66.96M 57.7M 54.63M 49.52M 92.9M 6.4B 93.37M 649M 250M 3.25B 251M 246M 10.28B P/E 2026 *
-54.6x
P/E 2027 * -382x
Enterprise Value 66.96M 57.7M 54.63M 49.52M 92.9M 6.4B 93.37M 649M 250M 3.25B 251M 246M 10.28B EV / Sales 2026 *
7.2x
EV / Sales 2027 * 4.08x
Free-Float
46.7%
Yield 2026 *
-
Yield 2027 * -
1 day+5.81%
1 week+11.68%
Current month+13.80%
1 month+10.29%
3 months+23.87%
6 months-0.09%
Current year-22.24%
1 week 9.9
Extreme 9.9
11.47
1 month 9.55
Extreme 9.5501
11.47
Current year 8.56
Extreme 8.56
14.75
1 year 8.56
Extreme 8.56
14.76
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2012
Director of Finance/CFO 69 27/09/2018
Chief Tech/Sci/R&D Officer - 04/06/2024
Director TitleAgeSince
Director/Board Member 91 31/12/1988
Chairman 56 13/02/2017
Director/Board Member 70 21/06/2016
Date Insider Type Main position Quantity % Market Cap. Importance
28/08/26 Free

Chief Technology Officer

2,451 0.0420%
23/06/26 Free

Director

2,500 0.0429%
08/04/26 Buy

Chief Executive Officer

1,000 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
+5.81%+11.68%-1.63%+20.10% 66.96M
+0.58%-2.20%+17.19%+120.98% 15.93B
+0.29%-3.46%+46.50%+170.67% 12.74B
+0.91%-2.52%-19.02%+25.08% 8.93B
+0.66%-2.47%+29.28%+147.34% 7.74B
-0.54%-3.72%-25.64%-15.51% 6.81B
-1.43%-2.54%+10.67%+26.34% 6.66B
+0.52%-0.64%+10.07%+27.21% 4.84B
-0.38%-1.58%+5.70%+5.59% 3.98B
+1.74%-1.26% - - 3.85B
Average +0.82%-0.87%+8.13%+58.65% 7.16B
Weighted average by Cap. +0.29%-2.47%+13.16%+84.05%

Financials

2026 *2027 *
Net sales 9.3M 8.01M 7.59M 6.88M 12.9M 888M 12.97M 90.11M 34.65M 452M 34.93M 34.16M 1.43B 16.4M 14.13M 13.38M 12.13M 22.75M 1.57B 22.87M 159M 61.11M 797M 61.59M 60.24M 2.52B
Net income -1.2M -1.03M -979K -887K -1.66M -115M -1.67M -11.63M -4.47M -58.33M -4.51M -4.41M -184M -200K -172K -163K -148K -277K -19.11M -279K -1.94M -745K -9.72M -751K -735K -30.72M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
45
Date Price Change Volume
11/09/26 US$11.47 +5.81% 69,771
10/09/26 US$10.84 -0.09% 71,306
09/09/26 US$10.85 +3.73% 14,969
08/09/26 US$10.46 +1.85% 47,707
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.47USD
Average target price
20.00USD
Spread / Average Target
+74.37%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!